Navigation Links
Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
Date:4/24/2013

HERSHEY, Pa. and ROCKVILLE, Md., April 24, 2013 /PRNewswire/ -- Immunomic Therapeutics, Inc., ("ITI," Hershey, PA), a leading developer of novel allergy immunotherapies, announced the preliminary results of a Phase I Study to treat individuals with an allergy to Japanese red cedar ("JRC").  The Company is pleased to report that the immunotherapeutic vaccine, JRC-LAMP-vax™, appears to have met all of its primary safety end points.  In addition, preliminary allergic marker results indicate a favorable trend in resolving the allergy.

Within the three subject sub-groups, (24 total patients) there were no reports of any Severe Adverse Events (SAE).  A small number of mild adverse events were reported in about 10% of the vaccinations, generally related to soreness associated with the intra-muscular injection.  The safety results are consistent with other clinical studies that have incorporated LAMP, which also showed the vaccine to be safe and well tolerated.  In addition to monitoring vaccine safety, subjects were also evaluated for immunological markers of allergy including circulating IgE, immunoglobulin G (IgG) and skin test reactivity. 

At the 2013 BIO International Convention, the CEO of Immunomic Therapeutics, Dr. William Hearl , presented the preliminary data for cedar specific IgE and for skin test reactivity.  All patients had stable IgE levels including those patients who entered the study as non-allergic to JRC.  This observation indicates that the vaccine does not induce a new IgE antibody response in either naive or allergic subjects.

Skin testing is perhaps the oldest and most reliable form of allergy testing.  Skin testing has been performed for 100 years and continues to be the test of choice for the diagnosis of allergic disease.  A number of the subject
'/>"/>

SOURCE Immunomic Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Immunomic Therapeutics Begins Phase I Japanese Red Cedar JRC-LAMP-Vax Vaccine Safety Study
2. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
3. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
4. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
5. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
6. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
7. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
8. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
9. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... a focus on Omega-3 therapies for cardiovascular disease and ... issued 763,752 common shares of the Corporation (the "Common ... the period of December 5 th , 2014 to ... Notes that is due on or before April 1, ...
(Date:3/26/2015)... and VANCOUVER, British Columbia, March 26, 2015 /PRNewswire/ ... provided a summary of clinical developments and announced ... Clinical Developments and Anticipated Near-term ... OncoGenex and Teva agreed to negotiate the termination ... OncoGenex. Negotiations of the final termination agreement are ...
(Date:3/26/2015)... S.C. , March 26, 2015 ... told by their existing PACS vendor their system ... (CMH) determined that they needed a better structured ... Hospital selected Avreo interWORKS due to its interface ... modern meaningful use standards through to the hospital,s ...
Breaking Medicine Technology:Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Clinch Memorial Hospital Modernizes Workflow with Avreo interWORKS 2
(Date:3/27/2015)... 27, 2015 When struck with the ... to know where to begin. The latest eBook ... accident attorney, offers accident victims a clear and concise ... to ensure their personal injury claim is seen through ... the first actions that should be taken immediately following ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... Industry is a professional and in-depth study on ... market with a focus on the Chinese ... of the industry including definitions, classifications, applications and ... provided for both the international and Chinese domestic ...
(Date:3/27/2015)... RI (PRWEB) March 27, 2015 April 2015 ... war – the Sesquicentennial. To honor America’s bloodiest war and ... Fort Adams Trust presents A Tribute to the Civil War ... PM, Friday, April 17, 2015, at the Jane Pickens Theater ... noted Civil War-Lincoln scholar, will serve as the master of ...
(Date:3/27/2015)... March 27, 2015 The ... Quaker-based, philanthropic, grant-making foundation committed to raising its ... healthcare is delivered. , The Scattergood Foundation and ... Behavioral Health Policy and Practice through the Annual ... Program App is designed to guide the ...
(Date:3/26/2015)... March 26, 2015 Alliance Healthcare Foundation ... and wellness for the poor and underserved in San ... for its annual $1 million award, the Innovation Initiative ... announce the 2015 round of our Innovation Initiative Award,” ... supported some incredibly creative and ambitious projects in the ...
Breaking Medicine News(10 mins):Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4Health News:SoundsLikeIBS Nominated For 3rd Annual Scattergood Innovation Award 2Health News:Applications Open for $1M Innovation Initiative Award from Alliance Healthcare Foundation 2
... Gerresheimer Stock in the SDAX as Per September 6, 2007 ... Outside the Normal Schedule, ... 5 September, DÜSSELDORF, Germany, September 3 Gerresheimer AG has,been listed ... following one of the largest IPOs of the year, with a total,issue ...
... we all know that tall parents are more likely to ... common genes that make people taller than others. Now, however, ... common variant of which directly influences height. , The ... the variant and a person carrying no copies is just ...
... 31, 2007) Two worldwide studies published in this week,s ... chronic obstructive pulmonary disease (COPD). The only U.S. site in ... in Eastern Kentucky, and was found to have some of ... fact, it had the second highest rate among women and ...
... designed for brain tumour therapy has shown promising tumour ... by scientists at The University of Nottingham. The project, ... and Human Development, will be featured in the September ... for brain cancers is particularly difficult for a number ...
... in on diacetyl, a key component of butter flavoring in ... key chemical ingredient in the buttery flavoring of microwave popcorn ... a lung disease that afflicts people who work in the ... Publishing in the September issue of the American Journal ...
... smoking are more likely to have sleep disturbances such ... sleep duration, and snoring loudly or breathing uncomfortably, according ... of the journal SLEEP. , The study, authored by ... focused on the responses of 16,396 and 19,386 pregnant ...
Cached Medicine News:Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 2Health News:High and mighty: first common height gene identified by researchers behind 'obesity gene' finding 3Health News:Two studies published in the Lancet 2Health News:Novel 3-D cell culture model shows selective tumour uptake of nanoparticles 2Health News:Scientists ID Likely Culprit in 'Popcorn Lung' 2Health News:Passive smoking increases sleep disturbance among pregnant women 2
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds....
... enables hospitals to standardize ... to a single temperature ... monitoring disposale probes and ... in their manufacture and ...
... Level 1 enables ... multiparameter patient monitors to ... series. Our temperature monitoring ... cables are superior in ...
Medicine Products: